The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for GeneTex sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
GeneTex is a biotechnology company that develops, licenses, and distributes its product of high-quality antibodies and research reagents. The company’s major products include primary antibodies, secondary antibodies, ELISA antibody pairs and kits, isotype controls, proteins and peptides, slides, lysates, serums and plasmas, reagents, research kits and research tools. It also offers research facilities in cancer, tumor markers, neuroscience, cell biology, metabolism, epigenetics, cardiovascular, immunology, development, cell markers, and others. GeneTexis is headquartered in Irvine, California, the US.
The key metrics of GeneTex related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As GeneTex is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as GeneTex.
For a detailed understanding of the performance of GeneTex, buy the report here.